These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 17433041

  • 1. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM.
    Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
    [Abstract] [Full Text] [Related]

  • 2. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Jul; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 3. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008 Jul; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 4. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis in 2 patients with end-stage renal disease on hemodialysis.
    Kim RH, Ma L, Hayat SQ, Ahmed MM.
    J Clin Rheumatol; 2006 Jun; 12(3):134-6. PubMed ID: 16755242
    [Abstract] [Full Text] [Related]

  • 5. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS, Sheller A.
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2007 Feb 23; 56(7):137-41. PubMed ID: 17318112
    [Abstract] [Full Text] [Related]

  • 13. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
    Deo A, Fogel M, Cowper SE.
    Clin J Am Soc Nephrol; 2007 Mar 23; 2(2):264-7. PubMed ID: 17699423
    [Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR.
    Eur J Radiol; 2008 May 23; 66(2):230-4. PubMed ID: 18372138
    [Abstract] [Full Text] [Related]

  • 15. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature.
    Introcaso CE, Hivnor C, Cowper S, Werth VP.
    Int J Dermatol; 2007 May 23; 46(5):447-52. PubMed ID: 17472669
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Transglutaminases: the missing link in nephrogenic systemic fibrosis.
    Parsons AC, Yosipovitch G, Sheehan DJ, Sangüeza OP, Greenberg CS, Sane DC.
    Am J Dermatopathol; 2007 Oct 23; 29(5):433-6. PubMed ID: 17890909
    [Abstract] [Full Text] [Related]

  • 19. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.
    Am J Kidney Dis; 2008 Jun 23; 51(6):966-75. PubMed ID: 18501784
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.